Verve Therapeutics Stock Alpha and Beta Analysis
| VERV Stock | USD 5.97 0.18 2.93% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Verve Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Verve Therapeutics over a specified time horizon. Remember, high Verve Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Verve Therapeutics' market risk premium analysis include:
Beta 1.93 | Alpha 0.44 | Risk 5.76 | Sharpe Ratio 0.0562 | Expected Return 0.32 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Verve |
Verve Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Verve Therapeutics market risk premium is the additional return an investor will receive from holding Verve Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Verve Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Verve Therapeutics' performance over market.| α | 0.44 | β | 1.93 |
Verve Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Verve Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Verve Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Verve Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Verve Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Verve Therapeutics shares will generate the highest return on investment. By understating and applying Verve Therapeutics stock market price indicators, traders can identify Verve Therapeutics position entry and exit signals to maximize returns.
Verve Therapeutics Return and Market Media
The median price of Verve Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 6.42 with a coefficient of variation of 14.53. The daily time series for the period is distributed with a sample standard deviation of 0.97, arithmetic mean of 6.69, and mean deviation of 0.84. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 | 01/03/2025 |
2 | Acquisition by Ashe Andrew D. of 36000 shares of Verve Therapeutics subject to Rule 16b-3 | 01/17/2025 |
3 | Verve Therapeutics Stock Price Up 5.6 percent - Whats Next - MarketBeat | 01/30/2025 |
4 | Verve Therapeutics Trading Up 6.7 percent Heres What Happened | 02/05/2025 |
5 | Verve Therapeutics Shares Gap Up Should You Buy | 02/06/2025 |
6 | Acquisition by Allison Dorval of 75000 shares of Verve Therapeutics at 6.01 subject to Rule 16b-3 | 02/07/2025 |
7 | Investors Who Lost Money on Verve Therapeutics, Inc. Should Contact Levi Korsinsky About Pending Class Action - VERV - ACCESS Newswire | 02/19/2025 |
8 | Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 ... | 02/27/2025 |
9 | Verve Therapeutics Full Year 2024 Earnings Beats Expectations | 02/28/2025 |
About Verve Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Verve or other stocks. Alpha measures the amount that position in Verve Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.95 | 0.9 | Days Of Inventory On Hand | 4.9E-5 | 4.3E-5 |
Verve Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Verve Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verve Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Verve Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Verve Therapeutics. Please utilize our Beneish M Score to check the likelihood of Verve Therapeutics' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Verve Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.